西伯利亚中部一所监狱中现行世界卫生组织复治方案的不足：治疗失败与耐多药结核病
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB.
作者信息
Kimerling M E, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, Matthys F
机构信息
Department of Medicine, School of Medicine, University of Alabama at Birmingham, USA.
出版信息
Int J Tuberc Lung Dis. 1999 May;3(5):451-3.
Multidrug-resistant tuberculosis (MDR-TB) threatens the progress of global control efforts. Prisons represent a high risk setting for development and transmission of MDR-TB. In a Siberian TB referral prison (Kemerovo region), the treatment failure rate is 35% (June 1996-March 1997), despite implementation of a strict DOTS program and use of the World Health Organization Category 2 re-treatment regimen for all new cases. Among 164 patients (December 1997-March 1998), initial resistance to isoniazid and rifampin is 22.6%. Such a rate is a warning call to reconsider prison control strategies, and importantly, to address the treatment regimens necessary to combat an institutional epidemic of MDR-TB.
耐多药结核病（MDR-TB）威胁着全球结核病控制工作的进展。监狱是耐多药结核病发生和传播的高风险场所。在西伯利亚一所结核病转诊监狱（克麦罗沃地区），尽管实施了严格的直接观察短程化疗（DOTS）计划，且对所有新病例采用了世界卫生组织2类复治方案，但治疗失败率仍达35%（1996年6月至1997年3月）。在164例患者中（1997年12月至1998年3月），对异烟肼和利福平的初始耐药率为22.6%。这一耐药率警示我们要重新考虑监狱结核病控制策略，重要的是，要确定应对监狱内耐多药结核病流行所需的治疗方案。
Zotero 插件